Instructions on whether genetic testing is required before use of Sotolaxib (AMG 510)

Before using Sotorasib (Sotorasib, AMG 510), genetic testing is a very critical step and one of the necessary steps before clinical use. Sotoracib is a KRAS G12C mutation inhibitor specifically targeted at patients with advanced or metastatic non-small cell lung cancer (NSCLC) and other solid tumors who carry KRAS G12C gene mutations. If a patient's tumor does not carry this mutation, the drug will not be as effective as it should be. Therefore, before deciding whether to use this drug, doctors usually recommend performing high-throughput sequencing (NGS) or other molecular testing methods to clarify the KRAS mutation status.

Genetic testing can not only confirm the presence ofKRAS G12C mutation, but also help doctors rule out other genetic variations that may affect treatment efficacy. For example, some patients may have other driver mutations (such as EGFR, ALK, ROS1, etc.). In these cases, sotorasib is not the first choice of treatment. Through testing, ineffective treatments can be avoided, unnecessary financial burdens and risks of side effects can be reduced. Test samples are generally derived from tumor tissue, and liquid biopsy (blood sample) can also be used. For patients who are inoperable or have difficulty sampling, liquid biopsy is a relatively convenient option.

In addition, genetic testing can also provide a reference for formulating individualized treatment plans. For patients whose test results are positive for KRAS G12C and meet the indications, doctors will decide whether to initiate sotorasib treatment and how to arrange the dose and course of treatment based on factors such as disease stage, previous treatment history, and organ function. At the same time, test results can also help determine whether patients may benefit from combination treatments, such as in combination with immunotherapy or other targeted drugs.

Overall, genetic testing plays an irreplaceable role in the treatment of sotoraxib. It is not only a necessary condition before medication, but also the embodiment of the concept of precision medicine. After patients are diagnosed with cancer, they should communicate with their doctors as soon as possible and complete comprehensive genetic testing so that the most effective targeted drugs can be selected at the right time for their condition. Through the combination of scientific testing and standardized medication, the clinical efficacy of sotoraxib can be maximized, the patient's survival period and quality of life can be improved.

Reference materials:https://www.drugs.com/